Monitoring of highly active antiretroviral therapy in HIV infection

Current Opinion in Infectious Diseases

Volumn 24, Issue 1, 2011, Pages 27-33

  Walker, A Sarah ^a   M Gibb, Diana ^a  

^a NONE

Author keywords

antiretroviral therapy; CD4; task shifting; toxicity; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONITORING; MORBIDITY; MORTALITY; TREATMENT OUTCOME; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; HIV; HIV INFECTIONS; HUMANS; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78751571233     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283423e0e     Document Type: Article

References (54)

1. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. WHO Geneva; 2010.
2. World Health Organization. Towards universal access: scaling up priority HIV/ AIDS interventions in the health sector: a progress report. Available from: http://www.who.int/hiv/pub/2009progressreport /en/index.html 2009. [accessed 18 October 2009.
3. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
4. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. Geneva: WHO. 2006.
5. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454-462.
6. Keiser O, MacPhail P, Boulle A, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009; 14:1220-1225.
7. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
8. Van Oosterhout JJ, Brown L, Weigel R, etal. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009; 14:856-861.
9. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
10. Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-484.
11. Mocroft A, Ledergerber B, Zilmer K, et al. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 2007; 21:1867-1875.
12. Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010; 55:451-459.
13. Bartlett JA, Fath MJ, Demasi R, etal. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-2064.
14. Hosseinipour MC, Van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
15. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48:1318-1322.
16. Kumarasamy N, Madhavan V, Venkatesh KK, etal. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 2009; 49:306-309.
17. Reynolds SJ, Kityo C, Mbamanya F, et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 2009; 14:293-297.
18. Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
19. Wallis CL, Mellors JW, Venter WD, et al. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-484.
20. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-417.
21. Melvin A, on behalf of the PENPACT-1 study team. PENPACT-1 (PENTA 9/ PACTG 390): a randomised trial of protease inhibitor (PI) vs. nonnucleoside reverse transcriptase inhibitor (NNRTI) combination antiretroviral (ART) regimens and viral load (VL) treatment switching strategies in HIV-1-infected ART-naive children age >30 days and
22. Ghosn J, Flandre P, Cohen-Codar I, et al. Long-term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ ritonavir monotherapy in the MONARK trial. HIV Med 2010; 11:137-142.
23. Delaugerre C, Flandre P, Chaix ML, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-2939.
24. Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Resistance to novel drug classes. Curr Opin HIV AIDS 2009; 4:531-537.
25. Hoffmann CJ, Charalambous S, Sim J, etal. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009; 49:1928-1935.
26. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010; 375:123-131.
27. Medina Lara A, Kigozi J, Amurwon J, et al. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring antiretroviral therapy in Uganda and Zimbabwe (DART Trial). In 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa, 19-22 July, 2009. Abstract TUSS103.
28. Keiser O, Tweya H, Braitstein P, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15:251-258.
29. Coutinho A, Mermin J, Ekwaru J, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. In 15th Conference on Retroviruses and Opportunistic Infections; Boston, 3-6 February; 2008. Abstract 125.
30. Oyomopito R, Lee MP, Phanuphak P, et al. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2010; 11:519-529.
31. The ART-LINC of IeDEA Study Group. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867-1874.
32. Koethe JR, Westfall AO, Luhanga DK, et al. A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics. PLoS One 2010; 5:e9680.
33. Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010; 51:85-92.
34. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153.
35. Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451.
36. Bendavid E, Young SD, Katzenstein DA, et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008; 168:1910-1918.
37. Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 2007; 21:1333-1340.
38. Vijayaraghavan A, Efrusy MB, Mazonson PD, et al. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 2007; 46:91-100.
39. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258-268.
40. May S, Gamst A, Haubrich R, et al. Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr 2010; 53:194-201.
41. Smith DM, May SJ, Perez-Santiago J, et al. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS 2009; 23:2151-2158.
42. Lynen L, An S, Koole O, et al. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 2009; 52:40-48.
43. Meya D, Spacek LA, Tibenderana H, et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc 2009; 12:3.
44. Lynen L, Van Griensven J, Elliott J. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Curr Opin HIV AIDS 2010; 5:1-5.
45. Koenig SP, Schackman BR, Riviere C, et al. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiv ing antiretroviral therapy in a resource-poor setting. Clin Infect Dis 2010; 51:600-608.
46. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV- infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised noninferiority trial. Lancet 2010; 376:33-40.
47. Shumbusho F, Van Griensven J, Lowrance D, etal. Task shifting for scale-up of HIV care: evaluation of nurse-centered antiretroviral treatment at rural health centers in Rwanda. PLoS Med 2009; 6:e1000163.
48. Cohen R, Lynch S, Bygrave H, etal. Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc 2009; 12:23.
49. Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health 2010; 8:8.
50. Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet 2009; 374:2080-2089.
51. Selke HM, KimaiyoS, Sidle JE, et al. Task-shifting of antiretroviral delivery from healthcare workers to persons living with HIV/AIDS: clinical outcomes of a community-based program in Kenya. J Acquir Immune Defic Syndr 2010; 55:483-490.
52. Wilson D, Keiluhu AK, Kogrum S, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 2009; 103:601-606.
53. Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis 2010; 201 (Suppl 1): S16-26.
54. Phillips A, Pillay D, Bennett D, etal. Predicted effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first-to second-line antiretroviral regimens in resource-limited settings. In 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, 2010. Abstract 596.